Background: Hypoxia inducible factor (HIF)-1α is a critical regulatory protein of cellular response to hypoxia and is closely related to angiogenic process.
Aims: To explore the potential role and the prognostic value of HIF-1α in urothelial carcinoma (UC).
Methods: Clinicopathological and follow-up data on 99 UC cases were reviewed and immunostained for HIF-1α, CD68, vascular endothelial growth factor (VEGF) and CD34 antigen. Tumour-associated macrophage (TAM) counts and HIF-1α expression were compared with clinicopathologic characteristics, overall survival (OS) and disease-free survival rates (DFS).
Results: High expression of HIF-1α was detected in 55 of 99 (55.6%) tumours. HIF-1α expression was correlated with tumour size, histological grade, tumour invasiveness and recurrence. VEGF and microvessel density (MVD) demonstrated their positive correlation with HIF-1α overexpression, supporting the correlation of HIF-1α up-regulation with tumour angiogenesis. Higher TAM infiltration was identified in high expression of HIF-1α cases rather than HIF-1α low expression cases (p = 0.002). Kaplan–Meier analysis found that HIF-1α overexpression and high TAM count was only associated with worse DFS (p = 0.009, p = 0.023) but was not associated with OS (p = 0.696, p = 0.141). Multivariate analyses indicated only tumour size (p = 0.038) to be an independently significant prognostic factor for OS, in addition, HIF-1α expression (p = 0.011), as well as histological grade (p = 0.038), and MVD (p = 0.004), to be independently significant prognostic factors for DFS.
Conclusions: Our results indicate that HIF-1α is a key regulator of the angiogenic cascade. We show that HIF-1α is an independent prognostic factor for disease-free survival.
Statistics from Altmetric.com
Competing interests: None declared.
Funding: This work was supported by a grant 5N-01 from Kaohsiung Medical University Hospital and the National Sun Yat-Sen University-Kaohsiung Medical University Joint Research Center, Kaohsiung, Taiwan.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.